Oligonucleotide synthesis is the chemical synthesis of comparatively short fragments of nucleic acids with designated chemical sequence. The technique is majorly useful in present laboratory practice because it offers a swift and inexpensive access to custom-made oligonucleotides of the desired sequence. It is also useful for conducting the molecular diagnosis in various diseases, such as detection of infectious diseases, such as hepatitis, SARS-COV2 as well as for diagnosis of cancer. The increased incidence of synthesized oligos utilized in molecular diagnostics and clinical applications is the factor for growing in market growth. Oligos are chemically classified and are applied in various relevant areas of scientific research and development. These have become a highlight in Molecular Biology and Biotechnology, owing to the synthetic DNA and cell-made DNA having same structural and chemical qualities. The antisense oligonucleotides are used to decrease the stages of protein synthesis by suppressing Micro RNA translation. This method is the basic of various therapies which are going through clinical trials for different types of cancer treatments. The role of favorable government support for the funding and increased Research and Development activities in the Pharmaceutical and Biotechnology Companies are driving the surge in the market revenue. Furthermore, the U.S. government has informed the key companies to produce a set of best practices for customer and sequence screening before the manufacture. Taken together, these protocols guarantee that synthetic DNA is used to advance research that is designed and aimed for public benefit. Upcoming technological advancements in gene-editing techniques are expected to become a game-changer in oligo synthesis. Recent progress in designing programmed nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)–Cas-associated nucleases, has majorly propelled the progress of gene editing from concept to clinical practice. The presence of a robust product range of oligonucleotide synthesis is also boosting the market growth. Apart from this, the high price of synthesized oligonucleotides and complexities in the therapeutic oligos is anticipated to impede the market growth.

In addition, the countries such as China, India, Singapore, and developing economies such as Brazil offer major growth opportunities for the oligonucleotide synthesis markets. This potential is significantly owing to the rising research and development investments by several companies in developing economies of the Asia Pacific and Latin America regions.

The global Oligonucleotide Synthesis Market is segregated on the basis of Product as Oligonucleotide-based Drugs, Synthesized Oligonucleotides, Reagents and Equipment. Based on Application the global Oligonucleotide Synthesis Market is segmented in Therapeutic Applications, Research Applications and Diagnostic Applications. Based on End User the global Oligonucleotide Synthesis Market is segmented in Hospitals, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, CROs and CMOs and Academic Research Institutes.

The global Oligonucleotide Synthesis Market report provides geographic analysis covering regions, such as Europe, North America, Asia Pacific, and Rest of The World. The Oligonucleotide Synthesis Market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Analysis

Adtbio Ltd., Agilent Technologies, Inc., Alnylam Pharmaceuticals, Inc., Biogen Inc., Biolegio B.V. and others are among the major players in the global Oligonucleotide Synthesis Market. The companies studied in terms of product strategy and various n several growth and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.

• In 2020, Danaher (US) acquired the Biopharma business from General Electric Company's (US) Life Sciences division. This subsidiary is known as ‘Cytiva’ and will play role of a standalone operating company within Danaher's Life Sciences segment. This acquisition empowered Danaher’s position in the oligo synthesizer and reagents market.
• In 2019, Thermo Fisher Scientific (US) entered into a contract with BioNTech SE (Germany). Under the agreement, Thermo Fisher provides nucleotides, enzymes, and other essential raw materials to support BioNTech's messenger RNA (mRNA) manufacturing platform. The four-year, nonexclusive licensing and supply agreement offers BioNTech rights to use Thermo Fisher's technologies as part of its clinical and commercial manufacturing processes.
• In 2020, Microsynth AG (Switzerland) introduced Primer-Probe Sets for SARS-CoV-2.

The global Oligonucleotide Synthesis Market has been segmented as below:

Oligonucleotide Synthesis Market, By Product

• Oligonucleotide-based Drugs
• Synthesized Oligonucleotides
• Reagents
• Equipment

Oligonucleotide Synthesis Market, By Application

• Therapeutic Applications
• Research Applications
• Diagnostic Applications

Oligonucleotide Synthesis Market, By End User

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• CROs and CMOs
• Academic Research Institutes

Oligonucleotide Synthesis Market, By Region

• Europe
• North America
• Asia Pacific
• Rest of The World

Oligonucleotide Synthesis Market, By Company

• Adtbio Ltd.
• Agilent Technologies, Inc.
• Alnylam Pharmaceuticals, Inc.
• Biogen Inc.
• Biolegio B.V.
• Biolytic Lab Performance Inc.
• Csbio
• Danaher Corporation
• Eton Bioscience, Inc.
• Eurofins Scientific
• Ionis Pharmaceuticals, Inc.
• Kaneka Corporation
• LGC Limited
• Maravai Lifesciences
• Merck Kgaa
• Microsynth Ag
• Sarepta Therapeutics, Inc.
• Tag Copenhagen A/S
• Therapeutic Players
• Thermo Fisher Scientific, Inc.
• Twist Bioscience Corporation

The report covers the below scope:

• Global Oligonucleotide Synthesis Market sizes from 2020 to 2026, along with CAGR for 2020-2026
• Market size comparison for 2019 vs 2026, with actual data for 2019, estimates for 2019 and forecast from 2020 to 2026
• Global Oligonucleotide Synthesis Market trends, covering comprehensive range of consumer trends & manufacturer trends
• Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global Oligonucleotide Synthesis Market
• Major market opportunities and challenges in forecast timeframe to be focused
• Competitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic management
• Comprehensive company profiles of the key industry players

The years considered for the study are as follows:

• Base year - 2019
• Estimated year - 2019
• Projected year - 2020
• Forecast period - 2021 to 2026

Report Scope:

The global Oligonucleotide Synthesis Market report scope includes detailed study covering underlying factors influencing the industry trends. The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Oligonucleotide Synthesis Market share. Major industry players with significant revenue share include Adtbio Ltd., Agilent Technologies, Inc., Alnylam Pharmaceuticals, Inc., Biogen Inc., Biolegio B.V. and others.

Why to Buy this Report:

• Gain detailed insights on the Oligonucleotide Synthesis industry trends
• Find complete analysis on the market status
• Identify the Oligonucleotide Synthesis Market opportunities and growth segments
• Analyse competitive dynamics by evaluating business segments & product portfolios
• Facilitate strategy planning and industry dynamics to enhance decision making

Target Audience:

• The report targeted towards the existing players in the industry is as follows:
• Market Manufacturers/Service Providers
• Market Wholesale/Traders
• Investment and Financial Institutions

Free and Paid Customization based on the requirement